TL;DR
XW4475 is a fatty acid-acylated UCN2 analog that selectively activates CRF2 receptors — exploiting tissue-specific cAMP signaling to simultaneously drive mTORC1-mediated muscle protein synthesis and HSL-mediated lipolysis. This makes it the first compound to achieve true simultaneous anabolism and fat loss. In DIO mice, Ecnoglutide + XW4475 produced 65.2% muscle composition and 12.8% fat mass vs. Ecnoglutide alone (55.9% muscle, 25.9% fat). ~100-hour half-life enables once-weekly SubQ dosing. Pre-clinical only; no human safety data; Phase 1 projected 2026–2027.
Key Facts
| Status | Pre-clinical / Pre-IND (ADA 2025; IND-enabling studies nearing completion) |
| Class | Long-acting UCN2 analog / selective CRF2 receptor agonist |
| Core mechanism | CRF2 → tissue-specific cAMP: muscle = mTORC1 anabolic; fat = HSL lipolytic |
| Half-life | ~100 hours (C18 fatty acid acylation → albumin binding) |
| Key benefit | True recomposition (anabolism + lipolysis simultaneously); cardioprotection via SERCA2a |
| Dosing | No validated human dose; preclinical: 3 nmol/kg + 3 nmol/kg Ecnoglutide |
| Main risk | Cardiovascular (vasodilation/orthostatic hypotension; compensatory tachycardia); no human data |
| Evidence | 21-day DIO mouse studies (ADA 2025); non-human primate studies nearing completion |
Mechanism Summary
The Core Insight: Tissue-Specific cAMP Interpretation
CRF2 receptor activation produces the same cAMP signal in muscle and fat, but the tissues interpret it differently:
CRF2R activation → Gs protein → ↑cAMP
In muscle:
cAMP → PKA / Epac → PI3K / Akt → mTORC1 → protein synthesis
→ FoxO phosphorylation → blocks Atrogin-1/MuRF1 → ↓ proteolysis
→ GLUT4 translocation → glucose uptake (insulin-independent)
In fat:
cAMP → PKA → Perilipin-1 dephosphorylation (exposes lipid core)
HSL phosphorylation → triglyceride hydrolysis → FFA release
Net effect: Raises the muscle protein synthesis ceiling; lowers the muscle proteolysis floor; simultaneously forces fat cells to release their stored triglycerides.
Why Not Just “Anti-Catabolic”?
Previous compounds claimed muscle preservation during caloric deficit. XW4475 is truly anabolic:
- mTORC1 activation = de novo protein synthesis (proven by S6K1 phosphorylation)
- FoxO sequestration = blocks ubiquitin-proteasome degradation
- GLUT4 translocation = fuels synthesis with glucose independent of insulin
CRF1 vs. CRF2 (Critical Distinction)
| Receptor | Location | Function | Side Effects if Activated |
|---|---|---|---|
| CRF1 | CNS / pituitary | HPA axis → ACTH → cortisol → anxiety | Stress, anxiety, catabolism |
| CRF2 | Peripheral (muscle, fat, heart, vasculature) | Vasodilation, inotropy, anabolism, lipolysis | Peripheral only |
XW4475 is 100% CRF2-selective — zero CRF1 binding. Fatty acid acylation keeps it peripheral (cannot cross BBB efficiently).
ADA 2025 Data (21-Day DIO Mice)
| Treatment | Body Weight | Muscle Composition | Fat Mass |
|---|---|---|---|
| Ecnoglutide alone | −17.2% | 55.9% | 25.9% |
| Ecnoglutide + XW4475 | −27.9% | 65.2% | 12.8% |
Key insight: The combination didn’t just preserve muscle — it increased muscle mass percentage while driving fat to 12.8% (competition-lean). The Ecnoglutide drove the caloric deficit; XW4475 redirected the resulting resources toward muscle accretion rather than allowing lean tissue loss.
Cardioprotective Effects
| Effect | Mechanism |
|---|---|
| ↑ Inotropy | Improved calcium handling via SERCA2a upregulation |
| ↑ Lusitropy | Faster cardiac relaxation |
| Vasodilation | eNOS activation → ↓ afterload |
Caution: Chronic CRF2 overactivation in some TAC (transverse aortic constriction) models showed exacerbation of cardiac stress. Dose titration to find the “Goldilocks” window is critical. Compensatory tachycardia from vasodilation is also plausible.
Wearable Biometric Effects
| Biomarker | Expected Effect | Rationale |
|---|---|---|
| RHR | Ambiguous | Vasodilation lowers afterload (→ lower RHR); compensatory tachycardia offsets (→ higher RHR). Net effect unclear without human data. |
| Recovery scores | Possible improvement | If muscle quality improves and lean mass is protected during aggressive fat loss, systemic resilience may improve. |
| Body composition | Most direct signal | Unlike most peptides, XW4475’s primary wearable signal may be scale/DEXA trends rather than HRV/sleep biometrics. |
Confidence level: Low. No human wearable data exists. These projections are based on mechanism and preclinical body composition data.
Safety
| Risk | Detail |
|---|---|
| Cardiovascular | Vasodilation → orthostatic hypotension possible; compensatory tachycardia is plausible; dose titration critical |
| No human data | All safety projections are preclinical; human tolerability profile entirely unknown |
| Orthostatic hypotension | Particularly relevant for athletes or anyone doing rapid posture changes |
| Pre-IND stage | Not ready for clinical use; monitor Sciwind IND filing progress |
Comparison to SLU-PP-332
| Factor | XW4475 | SLU-PP-332 |
|---|---|---|
| Primary mechanism | CRF2 agonist — resistance training mimetic (mTOR) | ERR agonist — endurance training mimetic (PGC-1α) |
| Muscle effect | Active accretion (mTORC1 + FoxO blockade) | Mitochondrial biogenesis, fiber type switching |
| Fat effect | Direct lipolysis (HSL/perilipin) | Indirect via energy expenditure |
| Cardiac | SERCA2a inotropy/lusitropy | PGC-1α cardioprotection |
| Evidence stage | Preclinical | Preclinical |
| Dosing | Weekly SubQ projected | Not established |
Stack together: XW4475 + SLU-PP-332 would theoretically cover both resistance and endurance exercise mimetic pathways — the most complete pharmacological exercise simulation currently on the horizon.
Best Stack Context
| Stack | Rationale |
|---|---|
| + Retatrutide | Retatrutide drives extreme catabolic pressure; XW4475 is the strongest pharmacological candidate for offsetting lean mass loss |
| + Ecnoglutide | Strongest preclinical recomposition data (ADA 2025); Sciwind has Ecnoglutide approved in China — co-formulation is the likely market path |
| + SLU-PP-332 | Resistance (XW4475) + endurance (SLU-PP-332) exercise mimetics together — broadest exercise pharmacology simulation |
| + BPC-157 | Rapid hypertrophy outpaces microvascular supply; BPC-157’s VEGF angiogenesis supports capillary expansion for new muscle tissue |
| + GHK-Cu | Oxidative stress management during increased mitochondrial β-oxidation from rapid lipolysis |
Dosing Summary
| Parameter | Value |
|---|---|
| Route | SubQ (once-weekly projected) |
| Half-life | ~100 hours (C18 fatty acid acylation) |
| Projected human dose | TBD (preclinical: 3 nmol/kg) |
| Combo (preclinical) | 3 nmol/kg XW4475 + 3 nmol/kg Ecnoglutide |
| Cycle | No validated schedule yet (pre-IND) |
Links
- Peptides MOC
- CRF2 receptor — mechanism anchor
- Exercise Mimetics — mechanistic context
- Retatrutide — lean mass protection during GLP-1 fat loss
- Ecnoglutide — strongest preclinical stack data
- SLU-PP-332 — endurance exercise mimetic pairing
- BPC-157 — microvascular support for new muscle
- GHK-Cu — ECM quality during rapid recomposition
- WN561 — cardiac output pairing